Lymphodepletion (LD) or conditioning is an essential step in the application of currently
used autologous and allogeneic chimeric antigen receptor T-cell (CAR-T) therapies as it …

Cellular therapies provide a curative‐intent option for patients with relapsedand refractory
lymphomas. Current options including high dose chemotherapyfollowed by autologous or …

Simple Summary B-cell lymphomas are the most commonly occurring blood cancer and the
second leading cause of cancer-related death among blood cancers. Chemotherapy and …

CD19‐directed chimeric antigen receptor (CAR) T‐cell therapy has had a dramatic impact
on the natural history and survival of patients with high‐risk B‐cell non‐Hodgkin lymphoma …

Chimeric antigen receptor T-cell (CAR T) therapy has been proven effective in the third-line
(and beyond) setting in patients with large B-cell lymphoma (LBCL). Until recently, high …

Background: Chimeric antigen receptor (CAR) T-cell therapy has produced promising
response rates in patients with B cell malignancies. However, previous meta-analyses have …

Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cell has changed
the treatment landscape of B-cell non-Hodgkin's lymphoma (NHL), especially for aggressive …

In the last decade, anti-CD19 CAR-T cell therapy has led to a treatment paradigm shift for B-
cell non-Hodgkin lymphomas, first with the approval for relapsed/refractory (R/R) large B-cell …

Chimeric antigen receptor modified T (CAR‐T) cell therapy against the CD19 antigen has
revolutionized the therapeutic landscape for patients with relapsed, refractory B cell non …

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma
subtype. Disease progression or relapse following frontline chemoimmunotherapy, largely in …